Business Description
Baxter International Inc
NAICS : 339112
SIC : 3841
One Baxter Parkway, Deerfield, IL, USA, 60015
Compare
Compare
Traded in other countries / regions
BAX.Austria
•
B1AX34.Brazil
•
BTL.Germany
•
BAX.Mexico
•
BAX.Switzerland
•
0QK8.UK
•
BAX.USA
Description
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. The company offers contract manufacturing services to pharmaceutical companies. The Hillrom transaction has added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's 2021 revenue came from more digitally connected offerings like its smart beds and Voalte medical communications app.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.11 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 1.94 | |||||
| Debt-to-EBITDA | 6.54 | |||||
| Interest Coverage | 4.36 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.31 | |||||
| Beneish M-Score | -2.28 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.4 | |||||
| 3-Year EBITDA Growth Rate | 3.7 | |||||
| 3-Year EPS without NRI Growth Rate | -3.8 | |||||
| 3-Year FCF Growth Rate | 5.4 | |||||
| 3-Year Book Growth Rate | 5.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 9.49 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 10.23 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.77 | |||||
| 9-Day RSI | 51.96 | |||||
| 14-Day RSI | 46.49 | |||||
| 6-1 Month Momentum % | -21.61 | |||||
| 12-1 Month Momentum % | -14.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.01 | |||||
| Quick Ratio | 1.33 | |||||
| Cash Ratio | 0.47 | |||||
| Days Inventory | 99.02 | |||||
| Days Sales Outstanding | 60.01 | |||||
| Days Payable | 48.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.85 | |||||
| Dividend Payout Ratio | 0.57 | |||||
| 3-Year Dividend Growth Rate | 14.1 | |||||
| Forward Dividend Yield % | 1.9 | |||||
| 5-Year Yield-on-Cost % | 3.95 | |||||
| 3-Year Average Share Buyback Ratio | 0.7 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.95 | |||||
| Operating Margin % | 9.62 | |||||
| Net Margin % | 7.12 | |||||
| ROE % | 11.42 | |||||
| ROA % | 3.67 | |||||
| ROIC % | 5.72 | |||||
| ROC (Joel Greenblatt) % | 18.57 | |||||
| ROCE % | 6.05 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.54 | |||||
| Forward PE Ratio | 14.7 | |||||
| PE Ratio without NRI | 30.54 | |||||
| Shiller PE Ratio | 15.53 | |||||
| Price-to-Owner-Earnings | 29.74 | |||||
| PS Ratio | 2.18 | |||||
| PB Ratio | 3.48 | |||||
| Price-to-Free-Cash-Flow | 27.46 | |||||
| Price-to-Operating-Cash-Flow | 16.71 | |||||
| EV-to-EBIT | 32.09 | |||||
| EV-to-Forward-EBIT | 19.28 | |||||
| EV-to-EBITDA | 17.55 | |||||
| EV-to-Forward-EBITDA | 13.26 | |||||
| EV-to-Revenue | 3.25 | |||||
| EV-to-Forward-Revenue | 2.93 | |||||
| EV-to-FCF | 41.08 | |||||
| Price-to-Projected-FCF | 1.49 | |||||
| Price-to-Median-PS-Value | 0.75 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.07 | |||||
| Earnings Yield (Greenblatt) % | 3.12 | |||||
| Forward Rate of Return (Yacktman) % | 9.92 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:BAX
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14,193 | ||
| EPS (TTM) ($) | 2 | ||
| Beta | 0.42 | ||
| Volatility % | 29.01 | ||
| 14-Day RSI | 46.49 | ||
| 14-Day ATR ($) | 1.434589 | ||
| 20-Day SMA ($) | 61.3305 | ||
| 12-1 Month Momentum % | -14.51 | ||
| 52-Week Range ($) | 57.49 - 89.7 | ||
| Shares Outstanding (Mil) | 503.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Baxter International Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||